Monitoring of the immune responses following mogamulizumab containing treatment in patients with adult T-cell leukemia-lymphoma (MIMOGA study)
Latest Information Update: 23 Aug 2022
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Adult T-cell leukaemia-lymphoma
- Focus Pharmacodynamics
- Acronyms MIMOGA
- 22 Aug 2022 Planned End Date changed from 31 Jul 2020 to 31 Jul 2027.
- 01 Feb 2022 Results of an analysis assessed the clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab published in the British Journal of Haematology
- 24 Apr 2019 Results demonstrating the presence of skin-directed autoantibodies after mogamulizumab treatment published in the Clinical Cancer Research.